Jeremie Vitte

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Venues

Journal of neuro-oncology

Nature communications

Clinical trials (London, England)

Communications biology

University of California Los Angeles David Geffen School of Medicine

Université d'Evry Val d'Essonne (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of California Los Angeles David Geffen School of Medicine

United States

Associate Project Scientist :: Department of Head and Neck Surgery

University of California Los Angeles - David Geffen School of Medicine

United States

Assistant Researcher :: Department of Head and Neck Surgery

House Research Institute

United States

Senior Research Associate/Staff Scientist :: Neural Tumor Research Laboratory

House Research Institute

United States

Postdoctoral Scientist :: Neural Tumor Research Laboratory

INSERM - Hôpital Pitié Salpêtrière

France

Postdoctoral Scientist :: Neurology and Experimental Therapeutics Laboratory

INSERM - Université d'Evry Val d'Essonne

France

PhD candidate :: Molecular Neurogenetics Laboratory

Education History

Université d'Evry Val d'Essonne

France

PHD

Université Paris Descartes

France

MSC

Université Paris-Sud

France

MSC

Université Henri Poincaré Nancy I

France

BSC

Publications

Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, David Cachia, Brigitte C Widemann, Derald E Brackmann, Joni K Doherty, Michel Kalamarides, Marco Giovannini
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of neuro-oncology 167 (2) (2024)
Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A Wright, Elizabeth A Flynn, Shannon L Stott, Marco Giovannini, Andrea I McClatchey
Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature communications 14 (1) (2023)
Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A Wright, Elizabeth A Flynn, Shannon L Stott, Marco Giovannini, Andrea I McClatchey
Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature communications 14 (1) (2023)
Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A Wright, Elizabeth A Flynn, Shannon L Stott, Marco Giovannini, Andrea I McClatchey
Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature communications 14 (1) (2023)
Verena Staedtke, Kara Anstett, David Bedwell, Marco Giovannini, Kim Keeling, Robert Kesterson, YooRi Kim, Bruce Korf, André Leier, Miranda L McManus, Herb Sarnoff, Jeremie Vitte, James A Walker, Scott R Plotkin, Deeann Wallis
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical trials (London, England) (2023)
Sara H Isakson, Anthony E Rizzardi, Alexander W Coutts, Daniel F Carlson, Mark N Kirstein, James Fisher, Jeremie Vitte, Kyle B Williams, G Elizabeth Pluhar, Sonika Dahiya, Brigitte C Widemann, Eva Dombi, Tilat Rizvi, Nancy Ratner, Ludwine Messiaen, Anat O Stemmer-Rachamimov, Scott C Fahrenkrug, David H Gutmann, Marco Giovannini, Christopher L Moertel, David A Largaespada, Adrienne L Watson
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications biology 1 (2018)
Jeremie Vitte, Fuying Gao, Giovanni Coppola, Alexander R Judkins, Marco Giovannini
Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nature communications 8 (1) (2017)

Jeremie Vitte.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jeremie Vitte